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Educational Aims
To improve understanding of:
• The relative benefits and limitations of evidence derived from different study 
designs and the role that real-life asthma studies can play in addressing limitations 
in the classical randomised controlled trial (cRCT) evidence base.
• The importance of guideline recommendations being modified to fit the 
populations studied and the model of care provided in their reference studies.
Key points
• Classical randomised controlled trials (cRCTs) show results from a narrow patient 
group with a constrained ecology of care.
• Patients with “real-life” co-morbidities and lifestyle factors receiving usual care often 
have different responses to medication which will not be captured by cRCTs if they 
are excluded by strict selection criteria.
• Meta-analyses, used to direct guidelines, contain an inherent meta-bias based on 
patient selection and artificial patient care.
• Guideline recommendations should clarify where they related to cRCT ideals (in 
terms of patient populations, medical resources and care received) and could be 
enhanced through inclusion of evidence from studies designed to better model the 
populations and care approaches present in routine care.
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Summary
Clinical practice requires a complex interplay between experience and training, research, 
guidelines and judgement, and must not only draw on data from traditional or classical 
randomised controlled trials (cRCTs), but also from pragmatically designed studies that 
better reflect real-life clinical practice. To minimise extraneous variables and to optimise 
their internal validity, cRCTs exclude patients, clinical characteristics and variations in 
care that could potentially confound outcomes. The result is that respiratory cRCTs often 
enrol a small, non-representative subset of patients and overlook the important inter-
play and interactions between patients and the real world, which can effect treatment 
outcomes.
Evidence from real-life studies (e.g. naturalistic or pragmatic clinical trials and observa-
tional studies encompassing healthcare database studies and cohort studies) can be com-
bined with cRCT evidence to provide a fuller picture of intervention effectiveness and 
realistic treatment outcomes, and can provide useful insights into alternative management 
approaches in more challenging asthma patients. The Respiratory Effectiveness Group 
(REG), in collaboration with the European Academy of Allergy and Clinical Immunology 
(EAACI) and the European Respiratory Society (ERS), is developing quality appraisal tools 
and methods for integrating different sources of evidence. A REG/EAACI taskforce aims to 
help support future guideline developers to avoid a one-size-fits-all approach to recom-
mendations and to tailor the conclusions of their meta-analyses to the populations under 
consideration.
Real-world research and its 
importance in respiratory 
medicine
Introduction
Contrary to what many of the guidelines pur-
port, patients refuse to fit into neat boxes or 
to behave in the logical and rational man-
ner expected by their clinicians. Addition-
ally, healthcare professionals (HCPs) often 
do not follow guidelines to the letter and as 
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a result may offer patients less-than-optimal 
therapy. Daily clinical practice requires a com-
plex interplay between experience and train-
ing, research and judgement and must draw 
on data not only from classical randomised 
controlled trials (cRCTs), but also from prag-
matically designed studies that better reflect 
real-life clinical practice.
Asthma guidelines have been developed to 
support the complex decisions faced by prac-
ticing clinicians by synthesising and summaris-
ing the data available in the field. They aim to 
signpost appropriate treatments and should 
be a useful reference for clinicians, especially 
general practitioners and other non-specialist 
HCPs who need evidence-based guidelines to 
help diagnose, manage and provide patients 
with informed treatment choices. However, 
guidelines can only be as robust as the evi-
dence on which they are based. To understand 
the true value of guidelines, it is important to 
understand the methodologies on which they 
are founded [1].
The historical systems used to rate the 
quality of evidence all put RCTs on top of the 
hierarchy and observational studies at the bot-
tom, just above the “no evidence” level (i.e., 
expert opinion). More recently, the Grading 
of Recommendations, Assessment, Develop-
ment and Evaluation (GRADE) system was 
established to help developers of guidelines. 
More than 70 organisations around the world 
(among them the American Thoracic Soci-
ety (ATS) [2], the World Health Organization 
(WHO) [3] and the Cochrane Collaboration [4]) 
now subscribe to this system for developing 
guidelines. GRADE categorises evidence as 
“very low”, “low”, “moderate” or “high” based 
on its perceived methodological quality and 
likelihood of outcome bias. By default, RCTs 
start as high-quality evidence, observational 
studies as low-quality evidence. But GRADE 
offers a unique and highly valuable feature: the 
opportunity to upgrade or downgrade these 
ratings based on the detailed methodologi-
cal characteristics of studies. Accordingly, the 
quality of RCTs can be diminished through 
poorly detailed design and execution, inconsis-
tency, indirectness, reporting bias and impre-
cision. Conversely, the quality of observational 
studies can be elevated and strengthened 
through use of robust methods of handling 
potential sources of bias (e.g. selection bias, 
recall bias, information bias, detection bias) 
and a priori study registration and planning.
The GRADE system has unequivocal 
value but it results in an inherent dependence 
on RCT evidence within clinical guidelines. 
This relates in part to the high robustness of 
evidence provided by well-conducted RCTs, 
but other factors need to be considered: 1) 
many researchers and experts have more 
experience in assessing the quality of evi-
dence coming from RCTs than from real-life 
studies; and 2) high-quality real-life studies 
are still scarce. While the importance of RCTs 
for establishing the efficacy and short-term 
safety profile of new therapies is unequivocal, 
they are not without their limitations when 
seeking to evaluate how therapies will be 
used and perform in the real world. It is nei-
ther practicable, nor affordable (considering 
that funds, manpower and materials available 
for research cannot be endlessly expanded), 
and sometimes not even ethical, to address 
all the clinical questions that arise in daily 
practice within an RCT.
RCTs are typically conducted in centres of 
excellence and are designed to minimise extra-
neous variables so that a direct cause-and-ef-
fect relationship can be discerned between 
an intervention and an observed outcome. 
Patient and clinical characteristics with the 
potential to confound an outcome, be they 
lifestyle characteristics (e.g. current smoking 
status), socioeconomic or educational char-
acteristics, behavioural characteristics (e.g. 
religious beliefs, medication attitudes) and/
or clinical characteristics (e.g. comorbidities, 
reversibility of airflow obstruction) are sys-
tematically controlled for, as are variability in 
intensity of clinical care and monitoring. In 
respiratory medicine, efficacy RCTs exclude 
approximately 95% of asthma and 90% of 
COPD routine care populations due to their 
strict inclusion criteria (see fig. 1) [5]. A recent 
study found that 45% of patients with a physi-
cian diagnosis of COPD did not meet the typi-
cal clinical trial criteria for defining COPD and 
noted that patients who were younger, female, 
not white, had diabetes or depression were 
under-represented in the cRCTs. The authors 
concluded that efficacy trials in COPD often 
enrol a small, non-representative subset of 
patients with physician-diagnosed COPD [6].
Thus, while respiratory guidelines are 
built upon a strong foundation of systematic 
appraisal of the available evidence (among 
which the highest GRADE levels are provided 
by cRCTs), there are many patients or clinical 
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patterns of care that do not feature amid that 
evidence and for whom practicing physicians 
must take a clinical “leap of faith” when making 
management decisions.
Combining evidence sources
Given the current economically constrained 
environment of research, a high proportion 
of RCTs are designed mostly to satisfy regis-
tration requirements. Therefore, they answer 
only very specific PICOT (Population details, 
Intervention, Comparison to controls, Out-
come, Time to outcome) questions restricted 
to evaluation of interventions in idealised 
populations and in optimised standards of 
care. As outlined before, the unavoidable 
result is a number of gaps in the evidence 
available to practicing clinicians when they are 
faced with making clinical conditions in more 
routine scenarios. Where data are unavail-
able, or unevaluable through the conventional 
cRCT route, there is a need to consider alter-
native study methodologies, such as prag-
matic  randomised controlled trials (pRCTs; 
see table 1) and observational studies.
There is increasing recognition of the need 
to look beyond the traditional cRCT to achieve 
a clearer picture of treatment outcomes when 
used outside a clinical trial setting, as is noted 
in the 2014 revised Global Initiative for Asthma 
(GINA) recommendations. GINA’s revised 
recommendations are built upon a “new” 
definition of asthma, one that recognises its 
heterogeneous nature and variability, and the 
need to tailor patient care to individual patient 
characteristics, modifiable risk factors, patient 
preference and practical issues to maximise 
the benefit that can be obtained from available 
medications.
Responding to calls for a more integrated 
view of the available evidence being used to 
inform practical, implementable clinical guid-
ance [7, 8], this paper considers what real-life 
evidence is available, how it can complement 
that from cRCTs and opportunities to use real-
life evidence to help guide treatment decisions 
in asthma.
900
1000a)
100%
38.4%
14.3%
All patients
No co-morbidity Pack-years <10 Regular ICS Symptoms
VAS <2.5 FEV1 50–85% Historical rev 12%
5.7% 3.7%
Asthma
2.1% 1.7% 1.3%
800
600
700
500
400
300
200
100
0
Su
bj
ec
ts
 n
800
900b) 100%
42.1%
15.2% 10.1% 9.2% 8.2% 7.2%
COPD
700
600
500
400
300
200
100
0
Su
bj
ec
ts
 n
All patients
S or XS Pack-years >15 No hay fever
VAS <7.5 No co-morbidity FEV1 30–70
Figure 1
Studies have shown that 
classical efficacy RCTs exclude 
about 90% for a) asthma 
and 95% for b) COPD routine 
care populations due to 
strict inclusion and exclusion 
criteria. a) For asthma clinical-
trial patients criteria included: 
visual analogue scale (VAS) 
<2; historical reversibility in 
FEV 12% within the last 12 
months; absence of significant 
co-morbidity; nonsmoker or if 
previous smoker (XS) a smoke 
burden <10 pack-years; regular 
use of ICS; symptomatic 
asthma (defined as either the 
use of short acting β2-agonist 
daily or nocturnal awakening 
due to asthma at least 
once a week). b) For COPD 
clinical-trial patients criteria 
included: VAS >7.5, absence 
of significant co-morbidity; 
smoker (S) or XS; a smoke 
burden of >15 pack-years; no 
history of hay fever indicating 
presence of atopy. Reproduced 
from [5] with permission from 
the publisher.
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What sort of evidence  
do we have?
Asthma cRCTs provide necessary, robust 
short-term safety and efficacy data for avail-
able interventions. Yet their high internal 
validity comes at the expense of their external 
validity; limiting the extent to which interven-
tion efficacy can be extrapolated to reflect real-
life effectiveness in the more heterogeneous 
populations managed in routine care.
Intervention effectiveness (rather than 
efficacy) is typically the focus of real-life 
studies, where “real-life” refers to pragmatic 
(or naturalistic) RCTs and observational 
studies designed to better reflect aspects 
of routine care than most cRCTs [9]. Thus a 
“real-life” study often includes wide patient 
populations and/or is designed with a man-
agement approach that mimics that of clin-
ical practice. Yet as Roche et al. [10] have 
observed, understanding whether or not a 
given study should be considered “real-life” 
is not always clear.
For instance, a trial may involve close 
patient follow-up (very different from usual 
care) yet include a broad patient population 
that is fairly representative of the general pop-
ulation with the condition of interest. Thus it 
is “real-life” in terms of population selection, 
but not in terms of its “ecology” (i.e. general 
modalities and context) of care. Conversely, 
an observational study can focus on outcomes 
in a highly selected patient population, yet 
involve no clinical intervention beyond usual 
care; representing a real-life study in terms of 
ecology of care but not patient selection.
To assist classification and interpretation 
of the available evidence, Roche et al. [10] pro-
pose an integrated framework of the evidence 
base for clinical research that classifies studies 
within a two-dimensional design space bound 
by a study population axis (ordinate) and an 
ecology of care axis (abscissa) (fig. 2a). The 
ecology of care axis categorises studies along 
a continuous scale from highly controlled effi-
cacy RCT management and follow-up, at one 
end, to usual care (real-life practice) at the 
other (fig. 2c). The population axis  categorises 
Table 1 Common similarities and differences between the design of classical and 
pragmatic RCTs
Feature of trial design Classical RCT Pragmatic RCT
Randomisation Yes Yes
Control group Yes Yes
Setting/ecology of care •	 Highly	controlled
•	 Specialised	centres	
(secondary or tertiary)
•	 Pragmatically	controlled
•	 Usual	care	(> primary care)
Patient population •	 Highly	selected
•	 Confirmed	diagnosis
Narrow (“pure”) population
•	 Pragmatically	selected
•	 Clinical	diagnosis
Broad (“real-life”) population
Inclusion/exclusion criteria Many Few
Adherence Very good (stimulated and 
monitored)
Low (real-world adherence)
Therapy •	 Blinded	(single-	or	double-
blind); or
•	 Open-label
Usually open-label to allow for 
effects of different technologies e.g. 
device or mode of administration
Comparator Placebo; and/or active 
treatment
Active treatment
Outcome Efficacy Real-life effectiveness (comparative 
effectiveness)
Safety Usually short-term Short-term and long-term
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a study population along a continuum from a 
highly selected population through to a clin-
ically diagnosed population and on to “man-
aged as condition X” (i.e. managed as the 
condition under evaluation with or without 
a properly confirmed physician diagnosis) (fig. 
2d). Any study can be positioned within this 
space depending on the degree to which its 
two components can be said to reflect real-
life. The position of a study within the space 
is not a marker of its quality; it is a descriptive 
classification designed to aid understanding 
and interpretation of the resulting evidence.
What do cRCTs tell us?
cRCTs are the cornerstones of the drug licens-
ing process. They typically compare the effi-
cacy of a new product against placebo or a gold 
standard management approach, and capture 
short-term safety data to ensure a new inter-
vention is both efficacious and safe (fig. 2b). 
They are designed to address specific PICOT 
questions, requiring identification of a highly 
characterised patient population, intervention, 
comparator, outcome and evaluation time. In 
other words, they tend to “purify” all study 
components in order to minimise the risk of 
missing a beneficial effect of the treatment.
Asthma treatment options
A systematic, Cochrane review of the evidence 
comparing anti-leukotriene agents and inhaled 
corticosteroids (ICS) in the management of 
recurrent or chronic asthma concluded that, as 
monotherapy, ICS display superior efficacy to 
anti-leukotrienes (particularly in patients with 
moderate airway obstruction) [11]. The review 
endorsed the current guideline position that 
ICS should be the first-choice preventer therapy 
in patients initiating maintenance asthma ther-
apy (with leukotriene modifiers as an option) 
[12, 13]. For those who achieve suboptimal con-
trol on low-dose ICS maintenance therapy, the 
addition of a long-acting bronchodilator (LABA) 
is recommended before increasing the dose of 
ICS or adding a leukotriene modifier or sus-
tained-release theophylline to low-dose ICS.
If one takes a moment to review some 
of the high-quality cRCT data underpinning 
these recommendations, it is of note that the 
cRCTs range in duration from 12 to 28 weeks, 
include compliance rates in excess of 90% 
and typically include a run-in period [14–17], 
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Figure 2
Integrated research framework, bounded by population and ecology of care axes running from highly 
selected to managed care populations (Y-axis) and from highly interventional to observational study design 
approaches (X-axis). Adapted from [10] with permission from the publisher.
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which introduces knowledge of observation 
and potential Hawthorne effects [18]. Follow-
ing consideration of the cRCT evidence base 
informing the recommendation, there is per-
haps a missing qualifying statement to advise 
that ICS are the most effective preventer drug: 
in short-term use for those asthma patients 
with optimal inhaler technique, substantial 
lung function impairment, 15% reversibility of 
airflow limitation, if they do not smoke and 
have excellent medication compliance.
Inhaler devices
While manufactures invest heavily in the 
design and development of inhaler devices, 
systematic reviews and guidelines conclude 
that there is no evidence that alternative 
inhaler devices (DPIs, breath-actuated pMDIs 
or hydrofluoroalkane pMDIs) are more effec-
tive than the pMDIs with a spacer for the deliv-
ery of ICS therapy [12, 13, 19].
Yet, there is perhaps a certain inevitability 
to these conclusions. cRCTs typically train par-
ticipants in the optimum use of their inhaler 
and require demonstration of effective use 
throughout, with extensive expert review at 
most trial visits. The missing qualifier within 
statements claiming device equivalence 
should perhaps be that all devices appear 
equal “when used optimally”. If the research 
question under consideration were: “which 
inhaler device is associated with the best 
outcomes in a broad, heterogeneous asthma 
population managed in a naturalistic setting?” 
the evidence may be less conclusive due to the 
high frequency of errors in inhaler technique 
with all types of device and the frequent lack of 
adequate patient education by trained HCPs.
What can real-life research 
tell us?
Real-life research offers insights into the inter-
actions between patient characteristics, pref-
erences and lifestyle and treatment outcomes 
that are often missed (excluded) from cRCTs. 
It also offers the opportunity to explore how 
these interactions differ between therapies 
and treatment modalities and to evaluate 
important clinical outcomes, such as asthma 
exacerbations, that can be underpowered in 
cRCTs owing to their short duration and their 
pre-selection of idealised patients in whom 
such outcomes are often relatively infrequent.
Real-life ecology of care
Studies designed to reflect a more naturalis-
tic, real-life management approach can pro-
vide interesting insights into the differences 
between cRCT management and routine care 
management, and the potential implications of 
ecology of care on treatment outcomes (fig. 2c).
Medication adherence, for example, is 
considered a key pillar of treatment effective-
ness, with optimum therapeutic outcomes 
only achievable if taken as prescribed. Yet 
adherence to chronic asthma medication in 
longer-term RCTs has been shown to drop dra-
matically over time, for instance from ∼78% at 
3 months to 50% by 2 years in one paediatric 
study (fig. 3) [20]. This contrasts markedly with 
the typical adherence rates of 75–125% seen 
in cRCTs [21–25]. Thus short-term classical tri-
als miss the potential to investigate long-term 
adherence effects on overall treatment out-
comes. Mapping cRCT adherence to routine 
care management assumes 100% compliance 
to interventions. It seems logical to expect that 
comparable products with variable adherence 
rates are likely to have variable asthma out-
comes; if products have differential adherence 
rates in real-life, this may change conclusions.
Real-life observational database studies and 
UK government-funded pragmatic trials, also 
suggest that the modality/route of administra-
tion of medication can have an effect on med-
ication persistence. A Canadian observational 
asthma study compared the persistence with 
therapy among new leukotriene receptor antag-
onist (LTRA) patients (n=2200) and new users 
of ICS (n=2200) [26]. Patients were matched 
for key clinical features of disease severity to 
minimise potential confounding by indication. 
Compliance was found to be significantly bet-
ter among LTRAs than for ICSs; indeed, if in 
both groups all medications filled were taken 
at the prescribed dose, the annual percentage 
of days on therapy for LTRA users would have 
been twice that for ICS users (38% versus 19%; 
p<0.0001). The authors concluded that the 
data indicate a far from optimal persistence to 
both LTRAs and ICSs in patients with asthma, 
but that the relatively superior persistence to 
LTRAs might result in better effectiveness.
These data bore out in ELEVATE, two 2-year 
pRCTs designed to investigate the real-life effec-
tiveness of 1) LTRA therapy compared with ICS 
for patients initiating maintenance asthma ther-
apy and 2) LTRA add-on compared with LABA 
add-on therapy in patients with uncontrolled 
asthma despite maintenance ICS therapy [27].
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ELEVATE’s pragmatic design differed from 
that of a cRCT by using broad inclusion criteria 
and evaluating effectiveness outcomes over 
an initial 2-month period, but also over a lon-
ger-term 2-year period (fig. 2c). The primary 
endpoint was asthma-related quality of life, 
a patient-oriented measure of effectiveness, 
assessed by the Mini Asthma Quality of Life 
Questionnaire (MiniAQLQ). At 2 months, ini-
tiation of LTRAs was equivalent to the guide-
line-recommended reference alternative 
treatment strategies in terms of the MiniAQLQ. 
At 2 years, true equivalence was not shown but 
there were no significant differences between 
LTRAs and the alternative treatment strategy 
for primary or secondary outcome measures. 
Interestingly, adherence rates were higher for 
patients randomised to receive LTRA, median 
65% adherence compared with 41% for ICS 
patients. These data suggest a potential prefer-
ence for oral LTRA therapy over ICS therapy, driv-
ing better outcomes for the LTRA patients than 
may have been anticipated based on  evidence 
from the registration cRCTs alone. The ELEVATE 
authors concluded that their findings suggest 
a need for caution when extrapolating results 
from cRCTs to the broad population of patients 
with asthma who are treated in community set-
tings and that clinical decisions should take into 
account data from both cRCTs and pRCTs.
As mentioned earlier, the inherent nature 
of cRCT design can also positively bias 
treatment outcomes by insisting on effec-
tive inhaler technique throughout the study 
period. The cRCT optimises the power of the 
study to evaluate the efficacy of the dispensed 
therapy but, in the real world, handling errors 
are common across all devices. Data from 
3654 patients receiving the implementing 
Helping Asthma in Real Life (iHARP) clinical 
service, found that 85–90% of patients, across 
all types of asthma inhalers make at least one 
potentially serious handling error and ∼70% 
multiple potentially serious errors [28]. Real-
life device studies tell us that patients have a 
range of abilities to use their inhalers correctly 
(as do their physicians), receive infrequent 
inhaler (and less-than-perfect) training and 
may not be fully adherent to their medication. 
This picture is markedly different to the cRCT 
environment of perfect inhaler technique, 
perfect technique training and retraining by 
expert, specialist staff and daily diary use to 
promote adherence.
Real-life populations: broader inclusion 
criteria
Studies that include a more heterogeneous 
asthma population, one that better reflects 
that population routinely treated in the com-
munity, provide opportunity to explore the 
interaction between comorbidities, lifestyle 
factors, patient characteristics and asthma 
treatment outcomes (fig. 2d).
Rhinitis
Several factors support more than a coinciden-
tal association between asthma and rhinitis; 
they share a similar epidemiology, common 
triggers, a similar pattern of inflammation and 
nasal challenge results in asthmatic inflamma-
tion, and vice versa.
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Figure 3
Long-term adherence to ICS. Short-term cRCTs will miss the interaction between real-life adherence and 
treatment outcomes. Reproduced from [20] with permission from the publisher.
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Yet despite the likely association and high 
incidence of comorbid asthma and rhinitis, 
patients with rhinitis are often excluded from 
cRCTs of asthma therapies [29, 30]. The Clin-
ical Outcomes with Montelukast as a Partner 
Agent to Corticosteroid Therapy (COMPACT) 
trial, however, included a broader asthma 
population, and examined whether asthma 
patients with comorbid allergic rhinitis 
responded differently to budesonide plus 
montelukast than patients without comor-
bid allergic rhinitis in terms of asthma con-
trol (lung function) [31]. In the subgroup 
of asthma patients with allergic rhinitis, a 
combined treatment approach that included 
montelukast and budesonide was found to 
provide significantly greater reductions in air-
flow obstruction than were achieved by dou-
bling the dose of budesonide (fig. 4) [32]. The 
results suggest a treatment approach that 
targets the airway inflammation common to 
both diseases may be beneficial for the large 
proportion of asthma patients who also suffer 
from allergic rhinitis. They also illustrate the 
difference in treatment outcomes that real-life 
features of asthma management (i.e. presence 
of comorbid conditions) may affect, and the 
potential limitations in assuming cRCT results 
hold true across all patients and patient sub-
groups managed in routine care.
Lifestyle: smoking
Smoking rates among patients with asthma 
are similar to those of the general popula-
tion, yet smoking is another feature of real-life 
known to interact with asthma outcomes [12]. 
Active smoking is associated with worsening 
asthma symptoms, accelerated decline in lung 
function, and impaired response to corticoste-
roids and so patients with a current smoking 
status are routinely excluded from asthma 
cRCTs [33–35]. The exclusion of smokers aims 
to minimise a potential source of bias and to 
evaluate a more direct relationship between 
the trial drug and its outcomes. Yet it also 
results in a sparse evidence base to guide clini-
cians in their asthma management decisions 
for the large proportion of asthma patients 
who continue to smoke.
More recently, a number of more prag-
matic trials and observational studies have 
attempted to address this gap in the evidence 
base by taking a more naturalistic approach to 
patient selection and including patients with 
some degree of cigarette exposure.
To explore the interaction of a current 
smoking status on ICS treatment, patients 
with mild asthma (n=95) were recruited to 
a multi-centre, double-blind, parallel-group 
study to compare the differential outcomes of 
inhaled beclomethasone dipropionate (BDP) 
at doses of 400 or 2000 µg in smokers and 
nonsmokers. Patients in both the smoking 
and nonsmoking arms were randomised to 
receive either 400 or 2000 µg BDP and the 
change in their morning peak expiratory flow 
(PEF) was measured over a 12-week outcome 
period. After 12 weeks of inhaled BDP therapy, 
there was a considerable difference in changes 
in morning PEF between smokers and non-
smokers. Interestingly, this difference was less 
pronounced in the 2000 µg BDP arm than in 
the 400 µg BDP arm (fig. 5). In other words, 
the magnitude of treatment effect on morn-
ing PEF was much greater in nonsmokers than 
in smokers at the 400 µg dosage, while it was 
similar at the high dosage. Similarly, while 
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The COMPACT study demonstrated the difference in outcomes associated with management of only lower 
airways inflammation (budesonide) compared with systemic (upper and lower airways) inflammation 
management (montelukast) in asthmatic patients without (a) and with (b) rhinitis. Reproduced from [31, 32] 
with permission from the publishers.
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there was a significantly higher exacerbation 
rate among smokers compared with non-
smokers in the 400 µg BDP treatment arm 
(6 versus 1, respectively), no significant differ-
ence was seen in exacerbation rates in patients 
receiving the high 2000 µg BDP daily dose (1 
versus 2, smokers versus non-smokers, respec-
tively). These data not only build on the results 
of studies showing diminished ICS efficacy 
in mild smoking asthma patients treated on 
low-dose ICS, but also suggest the disparity 
between treatment response in smokers and 
non-smokers appears to be reduced at higher 
ICS doses and may support consideration of 
higher dose ICS use in asthma patients with a 
current smoking status [34, 36].
Another treatment option with potential 
utility in smoking asthmatics is leukotriene 
modifiers [37]. The largest double-blind asthma 
cRCT involving asthmatic smokers conducted 
to date (albeit, a population of relatively mild 
asthma patients with limited smoking history) 
randomised to montelukast (10 mg once daily; 
n=347), medium-dose fluticasone (250 µg twice 
daily; n=336), and placebo (n=336), respectively. 
Over the 6-month outcome period, patients in 
both the fluticasone and montelukast treatment 
arms demonstrated significantly more days of 
asthma control than placebo and also signifi-
cant improvements on the secondary endpoint 
of change from baseline in mean daytime symp-
tom score were observed, compared with pla-
cebo, but no significant differences between 
montelukast and fluticasone. Smoking history 
and exposure appeared to play a role in response 
to therapy: patients who had a smoking history 
of <11 pack-years tended to show more benefit 
from fluticasone while those with a smoking 
history of >11 pack-years tended to show greater 
numerical benefit (in terms of asthma control) 
with montelukast. Overall, the study authors 
concluded that the data support consideration 
of montelukast as a new treatment option, an 
alternative to high-dose ICS, for asthma patients 
who cannot manage to stop smoking.
Lifestyle: overweight and obesity
The incidence of both asthma and obesity 
has increased across the developed nations 
in recent years [38, 39]. Indeed, incidence of 
asthma has been positively associated with 
obesity and evidence suggests that obesity may 
be associated with increased asthma severity 
[40]. To explore the potential interaction of body 
mass index (BMI) and asthma treatment out-
comes, PETERS-GOLDEN et al. [41] performed 
a post hoc analysis of four registered place-
bo-controlled trials studies that randomised 
over 3000 adult patients with moderate asthma 
to treatment with placebo, montelukast or ICS 
(beclomethasone). Patients were categorised 
as: BMI normal (<25.0 kg⋅m−2; 52% of patients), 
overweight (25–29.9 kg⋅m−2; 32%) and obese 
(≥30.0 kg⋅m−2; 16%) categories. Treatment 
groups were balanced for BMI, demographic 
characteristics and parameters of asthma con-
trol. The placebo response for the primary end 
point, asthma control days, was generally lower 
with increasing BMI. This held true across the 
secondary endpoints: forced expiratory vol-
ume in 1 s (FEV1), reliever use and nocturnal 
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awakening. Similarly, ICS response decreased 
with increasing BMI, yet the response to leu-
kotriene antagonist therapy remained stable 
across all three BMI categories. The authors 
concluded that their post hoc findings not only 
suggest BMI may influence the natural history 
of asthma control, but also that the effect may 
be class specific and that future prospective 
studies should explicitly evaluate the potential 
differential influence of BMI on active agents.
Comorbidities: long-term therapeutic profiles
Studies that take a more pragmatic approach 
to patient selection and harness long-term 
observational data can also be used to explore 
the adverse events profile of chronic asthma 
therapies.
Using data from the Quebec health insur-
ance databases, a new-user cohort study of 
respiratory patients (treated during 1990–2005) 
were followed until 2007, or until diabetes onset 
to evaluate any potential association of high-
dose ICS and diabetes risk. A nested case–con-
trol analysis was used to estimate the rate ratios 
of diabetes onset and progression associated 
with current ICS use, adjusted for age, sex, respi-
ratory disease severity and co-morbidity.
The cohort included 388  584 patients, 
of whom 30  167 had diabetes onset during 
5.5 years of follow-up. Current use of ICS was 
associated with a 34% increase in the rate 
of diabetes and rate of diabetes progression 
(RR 1.34, 95% CI 1.17–1.53). Moreover, the risk 
appeared to be dose related.
Again, these data demonstrated not only 
the value of more naturalistic study designs 
in terms of offering evaluation of longer-term 
outcome periods in an affordable, feasible 
way, but also the importance of considering 
the patient and their comorbidities rather 
than an isolated disease when selecting the 
optimum intervention.
Using real-life evidence 
to improve asthma 
management
As discussed, high-quality pRCTs and obser-
vational studies are already generating useful 
insights into the interactions between features 
of real-life asthma management and treatment 
outcomes. The next step is to improve under-
standing of how the available data should be 
used to help guide and inform clinical deci-
sion-making, which require the development 
and application of quality standards for the 
design and appraisal of real-life studies.
To support this next step, the Respiratory 
Effectiveness Group (REG) has published a 
checklist of key quality criteria that researchers 
and reviewers should consider when designing 
and reviewing real-life studies [42]. A taskforce 
has since been established, involving REG’s 
leading respiratory and academic experts in 
real-life research, in collaboration with the 
EAACI, to build and develop quality appraisal 
tools that the taskforce will use to identify 
high-quality, published asthma comparative 
effectiveness studies that address gaps in the 
cRCT evidence base and associated guidelines 
[43]. Studies deemed to be of high quality by 
the taskforce will be interpreted to establish 
what additional data they contribute, seeking 
to avoid and clarify any potential discrepancies 
between cRCT and real-life study findings.
Although some clinicians and academics 
have raised concerns that real-life evidence 
sometimes conflicts with that from cRCTs, this 
perception is largely one of misassigning the 
research question that the respective studies 
were seeking to address. To return to guideline 
recommendations on the optimum second 
step in asthma treatment, ICS is recommended 
as the most effective preventer drug. As earlier 
mentioned, this statement would be better if 
it were qualified that ICS is the most effective 
preventer drug in the populations and clini-
cal environments provided by the trials: i.e. in 
short-term use for those with perfect inhaler 
technique, substantial lung function impair-
ment, 15% reversibility, if they do not smoke 
and have very good medication compliance. 
The real-life studies discussed in this paper that 
support consideration of LTRA therapy rather 
than ICS do not conflict with the classical tri-
als, rather they relate to treatment options for 
smoking asthmatics, for asthma patients with 
comorbid rhinitis and for patients with subop-
timal adherence to inhaled therapy who may 
benefit from an oral alternative (perhaps a sub-
stantial proportion of the asthma population).
Conclusions
Comprehensive assessment of therapeutic 
strategies requires evaluation of both their 
efficacy under optimal conditions (high inter-
nal validity) and effectiveness in real-life 
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 populations and situations (high external 
validity). Various study designs are required 
to answer different questions about appropri-
ate and optimum use of available strategies 
and they should be viewed as complementary 
approaches to clinical research. Before inte-
grating the results of these studies into guide-
lines and clinical practice, the first prerequisite 
is the description of the study characteristics 
in terms of ecology of care and studied popu-
lation; both major determinants of the gener-
alisability of results.
Many (if not most) of the decisions that 
clinicians face have not (and cannot) be 
adequately tested in classical trials in the 
appropriate practice context. The movement 
towards more real-life studies is a reaction to 
the unmet clinical challenges faced by clini-
cians every day.
Features of the real world interact with 
cRCT therapeutic efficacy to produce the 
clinical outcomes seen in the community. It 
is inappropriate to assume a one-size-fits-all 
approach and that cRCT findings and guide-
line recommendations can be effectively 
extrapolated to all patients managed in rou-
tine care. By excluding important real-life 
factors (extraneous variables), the internal 
validity of a trial and “robustness” of the data 
increase, but only for the increasingly nar-
row group of patients for whom the results 
are relevant. Few community-based patients 
are managed in the idealised settings of a 
cRCT; some patients have only one diag-
nosis but most have co-morbidities, and 
real-life co-morbidities and lifestyle factors 
often result in different responses to medica-
tion, responses that are not captured if such 
patients are routinely excluded from cRCTs.
What is required is a more careful, thought-
ful approach to guideline development and 
clinical care to avoid a one-size-fits-all approach 
to recommendations. While meta-analyses of 
trials have their place, and may form the basis 
of some guideline recommendations, their 
conclusions need to be relevant and tailored to 
the population under consideration.
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